New key factor identified in the development of Alzheimer's disease

Jan 04, 2010

Inheritance of an extra copy of the gene- β -amyloid precursor protein, APP, in individuals with Down syndrome leads to the inevitable development of early onset Alzheimer's disease, known to be linked to the deposition of Amyloid β peptide or Aβ in the brain. However, a new study published online by Proceedings of the National Academy of Sciences identifies βCTF, a small protein found in APP, as a novel factor for the development of Alzheimer's disease related endosome abnormalities, which have also been tied previously to the loss of brain cells in Alzheimer's disease.

"In the study, using the cells from individuals with that are genetically predisposed to developing , we showed that elevated levels of βCTF, independent of Aβ, cause a specific pattern of endosome defects with similar pathology of brain cells in Alzheimer's disease," said Ying Jiang, PhD, lead author and clinical instructor in the Department of Psychiatry at NYU Langone Medical Center. "Our research was successfully able to pinpoint that βCTF causes Alzheimer's disease -related endosome defects and that we could successfully reverse these endosome defects by lowering βCTF levels in the cells."

Endosomes are membrane compartments in cells that support cell survival by absorbing outside nutrients and are crucial in neuronal functions. In Alzheimer's disease, endosome abnormalities are the earliest neuropathologic features to develop, appearing even earlier in cases where one of several major genetic risk factors for the disease in inherited. Endosomes are also suspected sites of Aβ production in the cells.

"In the field of Alzheimer's research, we have been questioning whether Aβ is the only target to better understand the progression of Alzheimer's disease and if lowering Aβ is the only hoped-for therapy," said Ralph Nixon, MD, PhD, professor, psychiatry and cell biology, director, NYU Center of Excellence on Brain Aging and the Silberstein Alzheimer's Institute at NYU Langone Medical Center. "This study demonstrates that an alternative protein factor, βCTF, derived from the gene APP, is also unequivocally involved in Alzheimer's disease and may be of additional importance for the development of future effective therapies."

Explore further: Treatment for overactive bladder and irritable bowel syndrome advanced through pioneering research

Related Stories

Novel role of protein in generating amyloid-beta peptide

Apr 27, 2009

A defining hallmark of Alzheimer's disease is the accumulation of the amyloid β protein (Aβ), otherwise known as "senile plaques," in the brain's cortex and hippocampus, where memory consolidation occurs. Researchers ...

Recommended for you

The impact of bacteria in our guts

13 hours ago

The word metabolism gets tossed around a lot, but it means much more than whether you can go back to the buffet for seconds without worrying about your waistline. In fact, metabolism is the set of biochemical ...

Stem cell therapies hold promise, but obstacles remain

14 hours ago

(Medical Xpress)—In an article appearing online today in the journal Science, a group of researchers, including University of Rochester neurologist Steve Goldman, M.D., Ph.D., review the potential and ch ...

New hope in fight against muscular dystrophy

15 hours ago

Research at Stockholm's KTH Royal Institute of Technology offers hope to those who suffer from Duchenne muscular dystrophy, an incurable, debilitating disease that cuts young lives short.

Biologists reprogram skin cells to mimic rare disease

Aug 21, 2014

Johns Hopkins stem cell biologists have found a way to reprogram a patient's skin cells into cells that mimic and display many biological features of a rare genetic disorder called familial dysautonomia. ...

User comments : 0